At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 179 enrolled
Drug / intervention
MultiHance 0.1 mmol/kg +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain
In Brief
A Phase 4 clinical trial evaluating MultiHance 0.1 mmol/kg, Dotarem, and 1 other intervention for Brain Disease. Completed, enrolled 179 participants across 1 site.
Detailed Summary
This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedFeb 2014
Primary CompletionMar 2015
TodayJul 2026
First PostedFeb 25, 2014
Enrollment StartFeb 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.4 years ago
Interventions
MultiHance 0.1 mmol/kgdrug
MultiHance administered at 0.1 mmol/kg
Dotaremdrug
Dotarem administered at 0.1 mmol/kg
MultiHance 0.05 mmol/kgdrug
MultiHance administered at 0.05 mmol/kg